key: cord-0737927-leb2zx9q
authors: van Kruijsdijk, Rob CM; de Jong, Pim A; Abrahams, Alferso C
title: Pulmonary vein thrombosis in COVID-19
date: 2020-10-31
journal: BMJ Case Rep
DOI: 10.1136/bcr-2020-239986
sha: 7be1d41397c28ad67e53eb01dc5cf52294da9d96
doc_id: 737927
cord_uid: leb2zx9q

nan

A 60-year-old woman was admitted to our hospital because of impending respiratory insufficiency 3 days after she was diagnosed with COVID-19 by PCR for SARS-CoV-2 performed on a nasopharyngeal swab. Her medical history included end-stage kidney disease due to hypertensive nephrosclerosis for which she was undergoing maintenance haemodialysis. At presentation, she had a respiratory rate of 36/min and 60% oxygen saturation on pulse oximetry. After starting oxygen via a nonrebreather mask, blood gas analysis showed a pCO 2 of 27 mm Hg and a pO 2 of 252 mm Hg. Chest radiography revealed diffuse bilateral consolidations, suspect for (viral) infection and fluid overload. She received ceftriaxone and low-molecular weight heparin (LMWH) prophylaxis for venous thromboembolism. Because of respiratory deterioration on the following day a pulmonary CT angiography (CTA) was made, which did not show pulmonary embolism, but revealed a pulmonary vein thrombosis (PVT) in the right upper lobe ( figure 1A ). There were no signs of pulmonary infarction, right ventricular failure or systemic arterial emboli. She was treated with therapeutically dosed LMWH. She gradually recovered and was discharged after 2 weeks. The LMWH was switched to acenocoumarol. Five weeks after the PVT diagnosis the acenocoumarol was discontinued because of anticoagulant-related bleeding complications. At that time, a repeat pulmonary CTA was made which showed no more signs of PVT (figure 1B).

PVT is a rare and probably underdiagnosed condition that can present with dyspnoea, cough, chest pain, haemoptysis and respiratory insufficiency, and may cause systemic arterial emboli leading to complications such as stroke, renal infarction and limb ischaemia. [1] [2] [3] [4] It is most often seen in patients with lung cancer and after pulmonary surgery. 4 To our knowledge, this is the first reported case of PVT in COVID-19. It is conceivable that PVT may result from the hypercoagulable state in COVID-19. 5 Treatment should be determined on an individual basis and can include anticoagulant therapy, thrombectomy and/or pulmonary resection. 4 Contributors RCMvK was involved in the care and management of the patient, and contributed to the initial drafting and critical revision of the manuscript. PAdJ was involved in the care and management of the patient, and contributed to the critical revision of the manuscript and provided the images. ACA was involved in the care and management of the patient, and contributed to the conception and critical revision of the manuscript.

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests PAdJ's department receives research support from Philips Healthcare, outside the submitted work.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. 

► Pulmonary vein thrombosis is a rare and probably underdiagnosed condition that may present with dyspnoea, cough, chest pain and/ or haemoptysis and can cause systemic arterial emboli. ► Pulmonary vein thrombosis may result from the hypercoagulable state in COVID-19.

Pulmonary vein thrombosis

Renal infarction in a patient with pulmonary vein thrombosis after left upper lobectomy

Stroke caused by a pulmonary vein thrombosis revealing a metastatic choriocarcinoma

Pulmonary vein thrombosis: a recent systematic review

Coagulation abnormalities and thrombosis in patients with COVID-19

Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/ BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.Become a Fellow of BMJ Case Reports today and you can: ► Submit as many cases as you like ► Enjoy fast sympathetic peer review and rapid publication of accepted articles ► Access all the published articles ► Re-use any of the published material for personal use and teaching without further permission

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.Visit casereports.bmj.com for more articles like this and to become a Fellow